Norovirus antibody

A nanoantibody comprising a polypeptide described in the following (a), (b), or (c):

• (a) a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO:
• 1, SEQ ID NO:
• 5, SEQ ID NO:
• 9, or SEQ ID NO:
• 13;
• (b) a polypeptide consisting of an amino acid sequence comprising a substitution, deletion, insertion and/or addition of one or several amino acids with respect to the amino acid sequence as set forth in SEQ ID NO:
• 1, SEQ ID NO:
• 5, SEQ ID NO:
• 9, or SEQ ID NO:
• 13;
• and
• (c) a polypeptide consisting of an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence as set forth in SEQ ID NO:
• 1, SEQ ID NO:
• 5, SEQ ID NO:
• 9, or SEQ ID NO:
• 13,
• wherein the nanoantibody inhibits infection of intestinal cells with HuNoV GII.4, and
• wherein the nanoantibody comprises the amino acid sequences of complementarity-determining regions 1 to 3 (CDR1, CDR2 and CDR3) of the following (A), (B), (C) or (D):
• (A) CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
• 17,
• CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
• 18, and
• CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
• 19;
• (B) CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
• 20,
• CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
• 21, and
• CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
• 22;
• (C) CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
• 23,
• CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
• 24, and
• CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
• 25;
• and
• (D) CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
• 26,
• CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
• 27, and
• CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
• 28.

A nucleic acid as set forth in SEQ ID NO:

• 2, SEQ ID NO:
• 6, SEQ ID NO:
• 10, or SEQ ID NO:
• 14.